Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
CSL (CMXHF)
In a report issued on May 29, David Stanton from Jefferies downgraded CSL to Hold, with a price target of A$108.00. The company’s shares closed last Friday at $68.20.
According to TipRanks.com, Stanton is a 4-star analyst with an average return of 11.9% and a 43.0% success rate. Stanton covers the Healthcare sector, focusing on stocks such as Clinuvel Pharmaceuticals, Telix Pharmaceuticals, and Mesoblast Limited.
Currently, the analyst consensus on CSL is a Moderate Buy with an average price target of $99.99, implying a 46.6% upside from current levels. In a report issued on May 14, Citi also maintained a Hold rating on the stock with a A$110.00 price target.
